Axel-Patrice Villani

Axel-Patrice Villani

Auto-generated profile, based on publicly available information

Axel-Patrice Villani

Department of Dermatology, Edouard Herriot Hospital, Lyon, France

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2015 in Journal of the American Academy of Dermatology
Verified
Journal Article
Closed access
AVAxel Patrice Villani
Axel Patrice Villani
MRMarie Rouzaud
Marie Rouzaud
MSMorgane Sevrain
Morgane Sevrain
TBThomas Barnetche
Thomas Barnetche
CPCarle Paul
Carle Paul
DJDenis Jullien
Denis Jullien

22 February 2019 in Journal of the European Academy of Dermatology and Venereology
Verified
Journal Article
Open access
PDF file
FAF. Amatore
F. Amatore
AVA.‐P. Villani
A.‐P. Villani
MTM. Tauber
M. Tauber
MVM. Viguier
M. Viguier
BGB. Guillot
B. Guillot
TDthe Psoriasis Research Group of the French Society of Dermatology (Groupe de Recherche sur le Psoriasis de la Société Française de Dermatologie)
the Psoriasis Research Group of the French Society of Dermatology (Groupe de Recherche sur le Psoriasis de la Société Française de Dermatologie)
These guidelines were developed by the psoriasis research group of the French Society of Dermatology with the aim of providing updated decision‐making algorithms for the systemic treatment of adult patients with moderate‐to‐severe psoriasis. Our algorithms were generated after rigorous evaluation of existing guidelines on the treatment of psoriasis and of publications concerning new systemic treatments, not yet incorporated into existing guidelines. A total of nine existing guidelines and 53 publications related to new systemic treatments were found to meet our criteria for use in the generation of the algorithms. We have proposed two new algorithms to assess therapeutic responses, both of which incorporate emerging criteria for evaluating treatment goals. Updated therapeutic strategy algorithms, incorporating both established and new systemic therapies, were also generated for the treatment of plaque psoriasis and psoriatic arthritis, together with recommendations for the treatment of particular forms of psoriasis and treatment of patients with comorbidities.

1 July 2014 in Journal of the European Academy of Dermatology and Venereology
Verified
Journal Article
Open access
PDF file
MRM. Rouzaud
M. Rouzaud
MSM. Sevrain
M. Sevrain
AVA.P. Villani
A.P. Villani
TBT. Barnetche
T. Barnetche
CPC. Paul
C. Paul
Marie BEYLOT-BARRYMarie BEYLOT-BARRY
Marie BEYLOT-BARRY
Psoriatic arthritis (PsA) is associated with psoriasis with a prevalence varying from 5.94% to 23.9%. The aim of this study was to assess if some psoriatic skin features are associated with a higher risk of PsA. A systematic literature search was carried out from 1980 to January 2013, in the Embase and Pubmed databases, using a combination of keywords including (Psoriasis)AND(PsA). Of the 2746 articles retrieved, 25 references were selected. Meta‐analysis was performed when possible. Mean age at psoriasis onset appeared to be similar among patients with skin disease alone and in those with PsA. There was no clinical type of psoriasis specifically associated with PsA, including pustular psoriasis of palms and soles. Nonetheless specific psoriasis localizations were significantly associated with an increased risk of developing PsA in one cohort study: scalp lesions [Hazard Ratio (HR) 3.89 (95% confidence interval (CI):2.18–6.94)] and intergluteal/perianal lesions [HR2.35 (95%CI:1.32–4.19)]. A similar association was found in two cross‐sectional studies. Nail involvement was significantly associated with PsA in the meta‐analysis [Odds Ratio (OR) 2.92 (95%CI2.34–3.64)], particularly onycholysis [OR2.38 (95%CI1.74–3.26)]. Moreover, nail psoriasis was also associated with distal interphalangeal joint arthritis. The extent of psoriasis appeared to be associated with PsA in one cohort study [≥3 sites:HR2.24 (95%CI1.23–4.08)], one case–control study [body surface area >75%:OR2.52 (95%CI1.33–4.75)] and three cross‐sectional studies. The meta‐analysis suggested a trend for an association between high PASI and PsA risk [mean difference 3.39 (95%CI0.94–5.83)]. Therefore, psoriasis patients with such clinical features may require a particular attention for early and close detection of PsA during the course of the cutaneous disease.

1 July 2014 in Journal of the European Academy of Dermatology and Venereology
Verified
Journal Article
Open access
PDF file
MSM. Sevrain
M. Sevrain
MRM.‐A. Richard
M.‐A. Richard
TBT. Barnetche
T. Barnetche
MRM. Rouzaud
M. Rouzaud
AVA.P. Villani
A.P. Villani
LML. Misery
L. Misery
Background: Palmoplantar pustular psoriasis (PPPP) is a variant of psoriasis whose the association with psoriatic arthritis (PsA) has been recently described. There is limited evidence regarding how to best reduce palmoplantar pustular psoriasis severity and to maintain remission once achieved.Objective: The aim of this study was to elaborate evidence‐based recommendations for PPPP treatment supported by a systematic literature review.Methods: A systematic literature search was carried out in Embase, Medline and Cochrane Library databases from 1980 to February 2013 searching for any trial in patients with PPPP assessing therapeutic interventions not including a systemic biotherapy. The selection of articles was limited to human subjects and English or French languages.Results: Among the 675 articles identified, 29 including one Cochrane review were analysed. The Cochrane review summarised 23 randomised controlled trials (RCTs) in chronic PPPP until February 2003, including 724 patients. The authors concluded that oral retinoid therapy (acitretin), photochemotherapy or combination of both, low dose of ciclosporin or topical corticosteroids under occlusion appeared to be helpful in relieving symptoms of PPPP. Since the publication of this review, 9 open studies on PPPP treatment have been published. Three new studies evaluated the benefits of PUVA on PPPP. They all showed a better efficacy of PUVA compared to UVB therapy. One open study concluded that a retinoid treatment with an arotinoid ethylesther showed a good efficacy. Five prospective studies (level of evidence of 3) assessed Laser Excimer UVB‐NB (Excimer 308 nm) in PPPP. The combined analysis of these studies showed that 64% of patients experienced an improvement of 70% at the end of treatment.Conclusion: Phototherapy, ciclosporin and topical corticosteroids seem to be able to control PPPP. However, the standard of care for PPPP remains an issue and there is a strong need for reliable RCTs to better define treatment strategies for PPPP.

1 June 2016 in Journal of the American Academy of Dermatology
Verified
Journal Article
Closed access
CFColine Faivre
Coline Faivre
AVAxel Patrice Villani
Axel Patrice Villani
FAFrançois Aubin
François Aubin
DLDan Lipsker
Dan Lipsker
MBMartine Bottaro
Martine Bottaro
DJDenis Jullien
Denis Jullien

19 March 2021 in Science Advances
Verified
Journal Article
Open access
PDF file
AVAxel Patrice Villani
Axel Patrice Villani
ARAurore Rozières
Aurore Rozières
BBBenoît Bensaid
Benoît Bensaid
KEKlara Kristin Eriksson
Klara Kristin Eriksson
AMAmandine Mosnier
Amandine Mosnier
MVMarc Vocanson
Marc Vocanson
This study highlights the key role of polycytotoxic CD8 + T cells in the severity of toxic epidermal necrolysis.